Key Takeaways
- • NeoGenesis Capital has launched its debut venture capital fund, targeting companies built on the genetic engineering platform of Colossal Biosciences, according to AltAssets.
- • Colossal Biosciences is a US biotechnology company best known for its efforts to revive extinct species.
- • The fund's focus on Colossal spinouts positions it in a niche tied to a single platform's commercialization pipeline.
- • Full terms of the fund, including target size, close and strategy details, were not available in the accessible portion of the source.
Summary
NeoGenesis Capital has launched its debut venture capital fund, according to AltAssets, with a mandate to invest in businesses developed using the genetic engineering platform of Colossal Biosciences. Colossal is a US biotechnology company best known for its attempts to revive extinct species.
The launch marks NeoGenesis's first vehicle and signals an institutional venture strategy built around spinouts from a single biotechnology platform. Investors evaluating the fund would be underwriting both the technology pipeline of Colossal and the venture manager's selection and development of portfolio companies.
The publicly accessible text of the report is limited, and the article was behind a premium paywall. Details such as fund size, target return, investor base, and portfolio company names could not be confirmed from the available source material.
The launch marks NeoGenesis's first vehicle and signals an institutional venture strategy built around spinouts from a single biotechnology platform. Investors evaluating the fund would be underwriting both the technology pipeline of Colossal and the venture manager's selection and development of portfolio companies.
The publicly accessible text of the report is limited, and the article was behind a premium paywall. Details such as fund size, target return, investor base, and portfolio company names could not be confirmed from the available source material.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.